Ani Pharmaceuticals (ANIP) Interest Expenses (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Interest Expenses data on file, last reported at $38.6 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 16.79% year-over-year to $38.6 million; the trailing twelve-month figure through Mar 2026 stood at $38.6 million (down 16.79% YoY), and the FY2025 full-year result was $48.3 million, down 6.19% from the prior year.
• Interest Expenses climbed to $38.6 million in Q1 2026, from $10.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $51.8 million in Q3 2024 to a low of $5.1 million in Q4 2024.
• A 5-year average of $28.3 million and a median of $24.1 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 57.84% in 2024 and surged 163.4% in 2025, its largest moves.
• Tracing ANIP's Interest Expenses over 5 years: stood at $7.4 million in 2022, then surged by 63.89% to $12.2 million in 2023, then slumped by 57.84% to $5.1 million in 2024, then jumped by 99.03% to $10.2 million in 2025, then surged by 276.46% to $38.6 million in 2026.
• Business Quant data shows ANIP's Interest Expenses at $38.6 million in Q1 2026, $10.2 million in Q4 2025, and $48.3 million in Q3 2025.